 SAN DIEGO, July 28, 2021 PRNewswire -- Viking Therapeutics, Inc. Viking NASDAQ: VKTX, a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2021, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended June 30, 2021: During the second quarter of 2021, we continued to make good progress with our lead program VK2809 for the treatment of NASH and fibrosis. 